<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586363</url>
  </required_header>
  <id_info>
    <org_study_id>Cavir food effect study</org_study_id>
    <nct_id>NCT02586363</nct_id>
  </id_info>
  <brief_title>Study of Evaluation of Cavir Tab. 0.5mg With Food Effect on Pharmacokinetics and Safety</brief_title>
  <official_title>A Randomized, Open-label, 3-way Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics and Safety of Single-dose Cavir Tab. 0.5mg With Baraclude Tab. 0.5mg in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this clinical trial, the investigator will clarify the difference in pharmacokinetics
      between the group single dose Cavir Tab. 0.5mg and single dose Cavir Tab. 0.5mg with high
      fatty meal for healthy adult volunteer.

      The investigators evaluate the effect of food intake on the absorption of Cavir Tab. 0.5mg.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of Entecavir.</measure>
    <time_frame>Within 6 Months After Final Visit of Subject</time_frame>
    <description>phamacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve, last (AUClast) of entecavir.</measure>
    <time_frame>Within 6 Months After Final Visit of Subject.</time_frame>
    <description>phamacokinetic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events.</measure>
    <time_frame>Within 6 Months After Final Visit of Subject</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve, infinite (AUCinf) of entecavir.</measure>
    <time_frame>Within 6 Months After Final Visit of Subject.</time_frame>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time at which the Cmax is observed (Tmax) of entecavir.</measure>
    <time_frame>Within 6 Months After Final Visit of Subject.</time_frame>
    <description>Pharmacokinetic parameter, Cmax is the peak plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (T1/2) of entecavir.</measure>
    <time_frame>Within 6 Months After Final Visit of Subject.</time_frame>
    <description>Pharmacokinetic parameter</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Baraclude Tab. 0.5mg, fasting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose Baraclude Tab. 0.5mg, fasting state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavir Tab. 0.5mg, fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose Cavir Tab. 0.5mg, fasting state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavir Tab. 0.5mg, high fatty meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose Cavir Tab. 0.5mg, high fatty meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baraclude Tab. 0.5mg, fasting</intervention_name>
    <description>After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)</description>
    <arm_group_label>Baraclude Tab. 0.5mg, fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cavir Tab. 0.5mg, fasting</intervention_name>
    <description>After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)</description>
    <arm_group_label>Cavir Tab. 0.5mg, fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cavir Tab. 0.5mg, high fatty meal</intervention_name>
    <description>After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)</description>
    <arm_group_label>Cavir Tab. 0.5mg, high fatty meal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male, aged 19 ~ 45 at screening date

          -  Subject`s weight is in range from -120 percentage to +120 percentage of ideal body
             weight which is calculated by { height (cm) - 100} * 0.9.

          -  The Subject is willing and able to provide written informed consent to participate in
             the study

        Exclusion Criteria:

          -  Subject has a history of clinically significant disease.

          -  Subject has a digestive disease (Crohn`s disease, ulcer, acute or chronic pancreatitis
             etc) or abdomen surgery (exclude, simple appendectomy or hernia operation).

          -  Subject has a hypersensitivity history which is clinically significance or additives.

          -  Subject is inappropriate to screening (disease history, physical examination, vital
             sings, electrocardiogram, laboratory test etc.)

          -  Subject has a laboratory test result as indicated by and one of the following.

               -  serum aspartate aminotransferase&gt; 1.25 * normal limit

               -  serum Total bilirubin &gt; 1.5 * normal upper limit

               -  serum CPK &gt; 1.5 * normal upper limit

               -  eGFR(estimated Glomerular Filtration Rate) calaulated by MDRD (Modification of
                  Diet in Renal Disease) formula &lt; 60 mL/min/1.73m2

          -  Subject is hypertension(SBP&gt;140mmHg or DBP&gt;90mmHg) or hypotension(SBP&lt;90mmHg,
             DBP&lt;60mmHg)

          -  Subject has a drug abusing history.

          -  Subject is currently abusing alcohol (more than 210 g/week), caffeine(more than
             5cups/day) or smoking(more than half pack).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Seok Yim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Dong-seok Yim</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Entecavir</keyword>
  <keyword>Food effect</keyword>
  <keyword>Cavir Tab 0.5mg</keyword>
  <keyword>Baraclude Tab. 0.5mg</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

